ABSTRACT
The combined endeavors of nanoscience and pharmaceutical science have surged the prominence of nanomedicine that has resolved several shortcomings of conventional drug delivery system, for instance, poor pharmacokinetics and biopharmaceutical properties, non-specific biodistribution, low therapeutic indexm and selective penetrability of drug molecules. A diverse range of nano-based drug delivery vehicles such as polymeric micelles, solid-lipid liposomes, magnetic nanoparticles, liposomes, nanotubes, virus, protein, and gene-based therapies have been extensively researched in the perspective of specifically delivering the therapeutic agent to the diseased organs. Several remarkable formulations were approved by FDA after successfully clearing the pre-clinical and clinical trials, which are marketed presently viz. Abraxane®, Myocet®, Rapamune® and many more. The therapy has emerged more advantageous for treating cancers and chronic diseases in terms of precisely acting on the specific diseased site and overcoming the side effects that usually encounter the non-specific healthy organs.
